In the Pten- and Stk11-deficient GEMM LUSC model, inhibition of neutrophil’s CXC chemokine receptors 1 and 2 (CXCR1/2)—which regulate their recruitment to the TIME110—combined with anti-PD1 treatment, decreased tumour masses, unlike single therapy treatment120. Here, STK11 is linked to neoplasm.